Tissue Regenix received approval from the Irish Health Products Regulatory Authority (HPRA), allowing the company to set up a logistics hub in Ireland for the distribution of its allograft products within the European Union.
HPRA regulates medicines and devices in Ireland for the benefit of people and animals, inspecting companies and facilities which test, make or distribute health products to ensure that they comply with relevant standards and legislation.
Tissue Regenix also signed an exclusive distributor contract with Spineart España for the distribution of its allograft products in Spain. Spineart operates in over 60 markets.
Daniel Lee, Chief Executive Officer of Tissue Regenix, said, “Receiving HPRA approval is a great step for Tissue Regenix, as it will provide a logistics hub for the distribution of our allograft products to the European market. Following this, we are delighted to be partnering with Spineart to bring our allograft products to more customers in the EU. Spineart has a large global footprint that we hope in time can be leveraged to bring our products to more customers internationally.”
Tissue Regenix received approval from the Irish Health Products Regulatory Authority (HPRA), allowing the company to set up a logistics hub in Ireland for the distribution of its allograft products within the European Union.
HPRA regulates medicines and devices in Ireland for the benefit of people and animals, inspecting companies and...
Tissue Regenix received approval from the Irish Health Products Regulatory Authority (HPRA), allowing the company to set up a logistics hub in Ireland for the distribution of its allograft products within the European Union.
HPRA regulates medicines and devices in Ireland for the benefit of people and animals, inspecting companies and facilities which test, make or distribute health products to ensure that they comply with relevant standards and legislation.
Tissue Regenix also signed an exclusive distributor contract with Spineart España for the distribution of its allograft products in Spain. Spineart operates in over 60 markets.
Daniel Lee, Chief Executive Officer of Tissue Regenix, said, “Receiving HPRA approval is a great step for Tissue Regenix, as it will provide a logistics hub for the distribution of our allograft products to the European market. Following this, we are delighted to be partnering with Spineart to bring our allograft products to more customers in the EU. Spineart has a large global footprint that we hope in time can be leveraged to bring our products to more customers internationally.”
Copy to clipboard 
